Loading...

We've got a brand new version of Simply Wall St! Try it out

Anxo Pharmaceutical

GTSM:6677
Snowflake Description

Proven track record with worrying balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
6677
GTSM
NT$2B
Market Cap
  1. Home
  2. TW
  3. Pharmaceuticals & Biotech
Company description

Anxo Pharmaceutical Co. Ltd., a specialty pharmaceutical company, focuses on the development, manufacturing, and sale of pharmaceutical products for medical professionals and patients in Taiwan and internationally. The last earnings update was 96 days ago. More info.


Add to Portfolio Compare Print
6677 Share Price and Events
7 Day Returns
7.3%
GTSM:6677
-1.7%
TW Pharmaceuticals
-0.5%
TW Market
1 Year Returns
-8.1%
GTSM:6677
16%
TW Pharmaceuticals
17.7%
TW Market
6677 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Anxo Pharmaceutical (6677) 7.3% 7.3% 11.3% -8.1% - -
TW Pharmaceuticals -1.7% 3.4% 3.5% 16% -10.7% -23.2%
TW Market -0.5% 2.8% 9.1% 17.7% 26.3% 26.1%
1 Year Return vs Industry and Market
  • 6677 underperformed the Pharmaceuticals industry which returned 16% over the past year.
  • 6677 underperformed the Market in Taiwan, Province of China which returned 17.7% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Anxo Pharmaceutical's competitors could be found in our database.

6677 Value

 Is Anxo Pharmaceutical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Anxo Pharmaceutical. This is due to cash flow or dividend data being unavailable. The share price is NT$35.84.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Anxo Pharmaceutical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Anxo Pharmaceutical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
GTSM:6677 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in TWD NT$0.37
GTSM:6677 Share Price ** GTSM (2019-11-18) in TWD NT$35.84
Taiwan, Province of China Pharmaceuticals Industry PE Ratio Median Figure of 26 Publicly-Listed Pharmaceuticals Companies 22.23x
Taiwan, Province of China Market PE Ratio Median Figure of 1,423 Publicly-Listed Companies 16.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Anxo Pharmaceutical.

GTSM:6677 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= GTSM:6677 Share Price ÷ EPS (both in TWD)

= 35.84 ÷ 0.37

95.8x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Anxo Pharmaceutical is overvalued based on earnings compared to the TW Pharmaceuticals industry average.
  • Anxo Pharmaceutical is overvalued based on earnings compared to the Taiwan, Province of China market.
Price based on expected Growth
Does Anxo Pharmaceutical's expected growth come at a high price?
Raw Data
GTSM:6677 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 95.8x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Taiwan, Province of China Pharmaceuticals Industry PEG Ratio Median Figure of 5 Publicly-Listed Pharmaceuticals Companies 0.89x
Taiwan, Province of China Market PEG Ratio Median Figure of 247 Publicly-Listed Companies 1.07x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Anxo Pharmaceutical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Anxo Pharmaceutical's assets?
Raw Data
GTSM:6677 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in TWD NT$13.86
GTSM:6677 Share Price * GTSM (2019-11-18) in TWD NT$35.84
Taiwan, Province of China Pharmaceuticals Industry PB Ratio Median Figure of 45 Publicly-Listed Pharmaceuticals Companies 2.17x
Taiwan, Province of China Market PB Ratio Median Figure of 1,936 Publicly-Listed Companies 1.44x
GTSM:6677 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= GTSM:6677 Share Price ÷ Book Value per Share (both in TWD)

= 35.84 ÷ 13.86

2.59x

* Primary Listing of Anxo Pharmaceutical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Anxo Pharmaceutical is overvalued based on assets compared to the TW Pharmaceuticals industry average.
X
Value checks
We assess Anxo Pharmaceutical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Anxo Pharmaceutical has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

6677 Future Performance

 How is Anxo Pharmaceutical expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Anxo Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
11.8%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Anxo Pharmaceutical expected to grow at an attractive rate?
  • Unable to compare Anxo Pharmaceutical's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Anxo Pharmaceutical's earnings growth to the Taiwan, Province of China market average as no estimate data is available.
  • Unable to compare Anxo Pharmaceutical's revenue growth to the Taiwan, Province of China market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
GTSM:6677 Future Growth Rates Data Sources
Data Point Source Value (per year)
Taiwan, Province of China Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 11.8%
Taiwan, Province of China Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 20.2%
Taiwan, Province of China Market Earnings Growth Rate Market Cap Weighted Average 11.4%
Taiwan, Province of China Market Revenue Growth Rate Market Cap Weighted Average 8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
GTSM:6677 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in TWD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
GTSM:6677 Past Financials Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income *
2019-06-30 847 92 16
2019-03-31 849 56 22
2018-12-31 850 20 29
2018-09-30 823 40 20
2018-06-30 795 59 11
2018-03-31 750 89 -9
2017-12-31 705 120 -29
2017-09-30 692 63 -22
2017-06-30 679 5 -15
2017-03-31 660 -7 -17
2016-12-31 642 -20 -20

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Anxo Pharmaceutical is high growth as no earnings estimate data is available.
  • Unable to determine if Anxo Pharmaceutical is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
GTSM:6677 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Anxo Pharmaceutical Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:6677 Past Financials Data
Date (Data in TWD Millions) EPS *
2019-06-30 0.37
2019-03-31 0.52
2018-12-31 0.67
2018-09-30 0.47
2018-06-30 0.26
2018-03-31 -0.21
2017-12-31 -0.69
2017-09-30 -0.54
2017-06-30 -0.38
2017-03-31 -0.43
2016-12-31 -0.49

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Anxo Pharmaceutical will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Check out Anxo Pharmaceutical's track record over time to understand how much the company has returned to shareholders and its earnings growth rate in the past.
  2. Anxo Pharmaceutical's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Anxo Pharmaceutical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Taiwan, Province of China market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Taiwan, Province of China market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Anxo Pharmaceutical has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

6677 Past Performance

  How has Anxo Pharmaceutical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Anxo Pharmaceutical's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Anxo Pharmaceutical has delivered over 20% year on year earnings growth in the past 5 years.
  • Anxo Pharmaceutical's 1-year earnings growth exceeds its 5-year average (43% vs 27.5%)
  • Anxo Pharmaceutical's earnings growth has exceeded the TW Pharmaceuticals industry average in the past year (43% vs 12.7%).
Earnings and Revenue History
Anxo Pharmaceutical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Anxo Pharmaceutical Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:6677 Past Revenue, Cash Flow and Net Income Data
Date (Data in TWD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 847.31 15.99 208.42 64.49
2019-03-31 848.63 22.32 211.17 67.88
2018-12-31 849.95 28.65 213.92 71.27
2018-09-30 822.61 19.92 215.99 70.09
2018-06-30 795.26 11.18 218.05 68.91
2018-03-31 750.01 -8.88 217.90 63.10
2017-12-31 704.76 -28.94 217.76 57.28
2017-09-30 692.04 -22.09 218.40 57.97
2017-06-30 679.32 -15.24 219.05 58.65
2017-03-31 660.43 -17.46 218.28 57.21
2016-12-31 641.53 -19.68 217.51 55.78
2015-12-31 631.04 -23.84 208.81 31.43
2014-12-31 643.22 26.36 185.44 26.69

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Anxo Pharmaceutical has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Anxo Pharmaceutical used its assets less efficiently than the TW Pharmaceuticals industry average last year based on Return on Assets.
  • Anxo Pharmaceutical has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Anxo Pharmaceutical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Anxo Pharmaceutical has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

6677 Health

 How is Anxo Pharmaceutical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Anxo Pharmaceutical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Anxo Pharmaceutical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Anxo Pharmaceutical's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Anxo Pharmaceutical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Anxo Pharmaceutical Company Filings, last reported 4 months ago.

GTSM:6677 Past Debt and Equity Data
Date (Data in TWD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 721.74 952.86 196.02
2019-03-31 721.74 952.86 196.02
2018-12-31 703.00 926.44 153.89
2018-09-30 703.00 926.44 153.89
2018-06-30 702.64 904.34 114.07
2018-03-31 702.64 904.34 114.07
2017-12-31 670.08 873.91 136.45
2017-09-30 670.08 873.91 136.45
2017-06-30 694.41 873.72 125.05
2017-03-31 694.41 873.72 125.05
2016-12-31 592.25 933.38 99.45
2015-12-31 618.27 650.75 149.95
2014-12-31 652.92 503.63 255.75
  • Anxo Pharmaceutical's level of debt (132%) compared to net worth is high (greater than 40%).
  • Unable to establish if Anxo Pharmaceutical's debt level has increased without past 5-year debt data.
  • Debt is not well covered by operating cash flow (9.6%, less than 20% of total debt).
  • Interest payments on debt are not well covered by earnings (EBIT is 2.2x annual interest expense, ideally 3x coverage).
X
Financial health checks
We assess Anxo Pharmaceutical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Anxo Pharmaceutical has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

6677 Dividends

 What is Anxo Pharmaceutical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Anxo Pharmaceutical dividends.
If you bought NT$2,000 of Anxo Pharmaceutical shares you are expected to receive NT$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Anxo Pharmaceutical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Anxo Pharmaceutical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
GTSM:6677 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Taiwan, Province of China Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 23 Stocks 2.8%
Taiwan, Province of China Market Average Dividend Yield Market Cap Weighted Average of 1323 Stocks 4.1%
Taiwan, Province of China Minimum Threshold Dividend Yield 10th Percentile 1.4%
Taiwan, Province of China Bottom 25% Dividend Yield 25th Percentile 2.6%
Taiwan, Province of China Top 25% Dividend Yield 75th Percentile 5.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Anxo Pharmaceutical has not reported any payouts.
  • Unable to verify if Anxo Pharmaceutical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Anxo Pharmaceutical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Anxo Pharmaceutical has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Anxo Pharmaceutical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Anxo Pharmaceutical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Anxo Pharmaceutical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

6677 Management

 What is the CEO of Anxo Pharmaceutical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Anxo Pharmaceutical has no CEO, or we have no data on them.
Management Team
Board of Directors
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NT$) Value (NT$)
X
Management checks
We assess Anxo Pharmaceutical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Anxo Pharmaceutical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

6677 News

Simply Wall St News

6677 Company Info

Description

Anxo Pharmaceutical Co. Ltd., a specialty pharmaceutical company, focuses on the development, manufacturing, and sale of pharmaceutical products for medical professionals and patients in Taiwan and internationally. The company primarily offers prescription, over the counter, and generic drugs. It offers its drugs in various therapeutic areas, such as cardiovascular or metabolism, CNS, diabetic, gastroenterology, respiratory, anti-infection, dermatology, ophthalmology/otology, nephrology, urology, orthopedics, and other. The company was founded in 2003 and is headquartered in Taipei, Taiwan.

Details
Name: Anxo Pharmaceutical Co., Ltd.
6677
Exchange: GTSM
Founded: 2003
NT$1,531,980,800
42,745,000
Website: http://www.anxo.com.tw
Address: Anxo Pharmaceutical Co., Ltd.
No.206, Nanking East Road,
8th Floor-3,
Taipei,
10489,
Taiwan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
GTSM 6677 Common Stock Taipei Exchange TW TWD 27. Jun 2018
Number of employees
Current staff
Staff numbers
0
Anxo Pharmaceutical employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 16:12
End of day share price update: 2019/11/18 00:00
Last earnings filing: 2019/08/14
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.